Journal articleCancers (Basel)2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.
- Journal
- Cancers (Basel)
- Published
- 3 February 2026
- Citations
- 3
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsSecond-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC NCT03634332↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.